PARTNERSHIP OPPORTUNITIES

We believe that partnership is a very effective way to advance any new treatment approach for the benefit of the patients, and would be delighted to consider the following collaboration opportunities:

  • Commercial Partnerships to enhance the commercial introduction of our D-PLEX100 lead development program to surgeons and the hospital surgical suite in various worldwide geographies.
  • License our PLEX™ platform technology delivery to improve proprietary product clinical outcomes for partners.
  • License-out our pipeline of early product candidate
    • PLEXPain Completed pre-clinical development of a product candidate that pairs PLEX matrix with a widely-used local anesthetic to reduce post-operative pain for extended period of time when applied into the surgical site.
    • PLEXCancer – Preclinical development of a product candidate that pairs PLEX matrix with a widely-used chemotherapeutic agents to be used locally to eradicate remaining cancerous cells following surgical tumor removal.
    • PLEX™ based Delivery of Proteins and Monoclonal Antibodies – Monoclonal antibodies were successfully encapsulated in PLEX™ and demonstrated prolonged released in vitro and in vivo (PK study) for several weeks while preserving the integrity of the antibody (both primary and secondary structures).
    • Anti-inflammatory research program.
    • Growth factors research program.

ARE YOU A POTENTIAL PARTNER?

If you are interested in exploring partnering with PolyPid please contact us at BD@polypid.com

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >